UBS analyst Matthew Weston maintained a Hold rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF248.00. The company’s shares closed yesterday at $242.28.
According to TipRanks, Weston is a 4-star analyst with an average return of 14.2% and a 73.68% success rate.
In addition to UBS, Roche Holding AG also received a Hold from Barclays’s Emily Field in a report issued yesterday. However, on April 2, J.P. Morgan maintained a Sell rating on Roche Holding AG (Other OTC: RHHVF).
The company has a one-year high of $323.78 and a one-year low of $237.81. Currently, Roche Holding AG has an average volume of 5,807.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Roche Holding AG (RHHVF) Company Description:
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
Read More on RHHVF:
- Roche receives FDA approval for molecular test to screen blood donors for malaria
- Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
- Rocheâs mixed myasthenia gravis data sending these stocks in opposite directions
- Tourmaline Bio might see weakness today after Roche MG data, says Truist
- Immunovant rallies after Chugai myasthenia gravis study failure
